Leila Dardaei

Leila Dardaei

Bristol-Myers Squibb Co. - New York / United States
Medical and Health Sciences / Medical Oncology
AD Scientific Index ID: 4385788
-
person_outline Leila Dardaei's MOST POPULAR ARTICLES
1-) Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung CancerJF Gainor, L Dardaei, S Yoda, L Friboulet, I Leshchiner, R Katayama, ...Cancer discovery 6 (10), 1118-1133, 201610032016
2-) Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198FAT Shaw, L Friboulet, I Leshchiner, JF Gainor, S Bergqvist, A Brooun, ...New England Journal of Medicine 374 (1), 54-61, 20164612016
3-) Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung CancerS Yoda, JJ Lin, MS Lawrence, BJ Burke, L Friboulet, A Langenbucher, ...Cancer discovery 8 (6), 714-729, 20183012018
4-) Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non–Small-Cell Lung CancerJF Gainor, D Tseng, S Yoda, I Dagogo-Jack, L Friboulet, JJ Lin, ...JCO precision oncology 1, 1-13, 20173012017
5-) Primary patient-derived cancer cells and their potential for personalized cancer patient careDP Kodack, AF Farago, A Dastur, MA Held, L Dardaei, L Friboulet, ...Cell reports 21 (11), 3298-3309, 20172152017